Key result
The article reviews the HOKUSAI VTE Cancer study comparing the efficacy and safety of endoxaban versus dalterapin for the treatment of venous thromboembolic complications in cancer patients.
Why the study?
Cancer is a major risk factor for venous thromboembolic complications (VTEC), prompting consideration of alternative anticoagulant therapy in these patients.
Does edoxaban improve efficacy and safety compared to dalteparin in cancer patients with VTEC?
Does edoxaban improve efficacy and safety compared to dalteparin in cancer patients with VTEC?
Answers are grounded in this paper and cite their sources.
This article reviews the HOKUSAI VTE Cancer study, which compares the direct oral anticoagulant edoxaban with dalteparin for treating VTE in cancer patients.
Cancer is one of the most significant risk factors for venous thromboembolic complications (VTEC). The article discusses the features of the treatment of cancer patients with VTEC. The issues of alternative anticoagulant therapy are considered. The article presents the results of HOKUSAI VTE Cancer study, the first completed study to compare the efficacy and safety of a direct oral anticoagulant endoxaban with a low molecular weight heparin dalterapin for the treatment of VTEC in cancer patients.
No takes yet. Share an insight, caveat, or question.
Yulia A. Fedotkina (2018) conducted a review in Venous thromboembolic complications (VTEC) in cancer patients. Endoxaban vs. Dalterapin was evaluated on Efficacy and safety. The article reviews the HOKUSAI VTE Cancer study comparing the efficacy and safety of endoxaban versus dalterapin for the treatment of venous thromboembolic complications in cancer patients.
Synapse has enriched 10 related papers. Consider them for comparative context: